All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Peg-IFN plus ruxolitinib in newly diagnosed patients with PV: Results from the COMBI II trial
|
Abbreviations: CR, complete remission; ORR, overall response rate; PBCR, peripheral blood cell count remission; Peg-IFN, pegylated interferon-alpha-2a; PR, partial remission; PV, polycythemia vera; TTS, Myeloproliferative Neoplasm Symptom Total Symptom Score; VAF, variant allele frequency. |
|
The phase II COMBI II trial assessed the safety and efficacy of Peg-IFN (45 μg/week) and ruxolitinib (10 mg twice daily) in 25 adult patients with newly diagnosed PV.1 Results from this trial with a 2-year follow-up were published in Blood Advances by Soerensen et al.1 |
| Key learnings |
|
The combination of Peg-IFN and ruxolitinib was well tolerated. Grade 1 and 2 anemia occurred in 68% and 20% of patients, respectively, which was managed with dose adjustments. In total, 12% and 16% of patients discontinued Peg-IFN and ruxolitinib, respectively. Sensory neuropathy was reported in 68% of patients. |
|
Significant reduction in TSS from baseline was observed at 14 days and 21 months. TTS items that reduced at more than half of the time points included abdominal discomfort (p < 0.001), night sweats (p < 0.001), itching (p < 0.05), and bone pain (p < 0.001). No TTS items increased during the trial. |
|
After 24 months, the PBCR, ORR, CR, and PR rates were 92%, 56%, 12%, and 44%, respectively. The overall molecular response rate at 24 months was 68% and the median JAK2V617F VAF after 2 years was 7% vs 47% at baseline. |
|
Results demonstrate that Peg-IFN and ruxolitinib were well tolerated, with high response rates and a reduction in JAK2V617F VAF, suggesting that this combination therapy with disease-modifying potential, has a beneficial impact on long-term disease control and quality of life in patients with newly diagnosed PV. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
